Evidence map›Paper›PMID 35914921›Full record

ArticleGut2023

Omics studies in gastroenterological and hepatological patient populations: current impact and future promise exemplified by a large study of HCV-infected livers.

Georg M Lauer

Abstract readComment
In one paragraph

Article in Gut, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Georg M LauerDivision of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts, USA glauer@mgh.harvard.edu.ORCID 0000-0002-9792-4271

Funding

Virology CoreU19AI082630 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI RAYMOND T CHUNG, GEORG Michael LAUER · 2009 to 2026
$48.1M
The development and pre-clinical assessment of novel HCV vaccines to generate T and B cell immunityU19AI159822 · NIAID · JOHNS HOPKINS UNIVERSITY · PI COX, ANDREA L · 2021 to 2025
$14.4M
The role of NK cells during acute HCV infection and antiviral therapyU19AI066345 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LAUER, GEORG MICHAEL · 2005 to 2014
$8.5M
Immunologic correlates of functional cure of HBV with immune checkpoint blockadeR01AI148648 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CHUNG, RAYMOND T, LAUER, GEORG MICHAEL · 2020 to 2024
$4.2M
T cells in HCV/HIV co-infectionR01DA046277 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI LAUER, GEORG MICHAEL · 2018 to 2022
$3.2M
NIAID NIH HHS R01 AI148648NIAID NIH HHS U19 AI066345NIAID NIH HHS U19 AI082630NIAID NIH HHS U19 AI159822NIDA NIH HHS R01 DA046277
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

GastroenterologyHepatitis CBiopsyGastrointestinal TractHepacivirusHumansLiverRNA, ViralRNA, ViralHEPATITIS CLIVERLIVER BIOPSYRNA EXPRESSION

Identifiers

PMID35914921
PMCPMC9889570

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.